CION Ameerpet
Pancreatic Cancer · Hereditary Risk & Genetics · Reviewed by CION Oncologists
Genetic testing for pancreatic cancer — who should actually get it
A germline test reads the genes you were born with, not the tumour. It answers two separate questions — whether anything in a treatment plan should change, and whether anyone else in the family needs watching. This page explains who is advised to have it, and what each possible result really means.
- Everyone diagnosed is offered it — NCCN advises germline testing whatever your age and whatever your family history.
- Germline is not tumour testing — one reads the genes you inherited, the other reads the cancer's own changes.
- A result changes two plans — what treatment is considered for you, and who in your family gets screened.
- A clear panel is not a full stop — a strong family history still counts, and can justify surveillance on its own.
17+
Cancer Specialists
on Panel
on Panel
35+
Centres Across
Telangana & AP
Telangana & AP
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Start here
Who Germline Testing Is Actually For
Most people who search for genetic testing pancreatic cancer are asking one of two quite different questions. Either you have just been diagnosed and a genetic test has been mentioned as part of the workup, or nobody in your own body is ill and you are here because a parent, a sibling or a grandparent had pancreatic cancer. The sample taken is the same in both cases. What the result is used for, and how much it can tell you, is not.
Germline testing looks at the genes you were born with and carry in every cell — the ones you inherited from your parents and could pass to your children. It is a blood draw or a saliva collection, and the analysis is run at an accredited genetics laboratory. It is not a scan. It does not look at your pancreas, and it cannot tell you whether a cancer is present today. It answers a narrower question: is there an inherited change that helps explain cancer in this family, and would it alter what is offered to you and to your relatives.
That is not the question a tumour test answers. If you have already been diagnosed, your team may also test the cancer itself, which looks at changes the tumour acquired during your lifetime rather than anything you inherited. Both can be useful and they are not interchangeable — the comparison further down this page sets out what each one is for.
For someone already diagnosed, NCCN guidance is straightforward: germline testing should be offered, whatever your age at diagnosis and whether or not anyone else in the family has been affected. The reason is practical rather than academic. Only a minority of pancreatic cancers are linked to an inherited variant, but a large share of the people carrying one have a family history that would never have flagged them under older, history-based criteria. BRCA2 is the gene found most often, and what a BRCA result means in pancreatic cancer covers that in detail — but the panel used is wider than BRCA alone.
For someone who has not been diagnosed, the useful order is the opposite of what most families expect. Testing is far more informative when it starts with the relative who actually had the cancer, because their result tells everyone else exactly what to look for. If that person has died or cannot be tested, testing an unaffected relative is still possible — it is simply harder to interpret, and a negative carries much less weight. Sorting out who to test first, and in what order, is the real work of a genetic counselling appointment for pancreatic cancer, more than the blood test itself.
Testing is a decision, not a formality. Some people want the information and act on it. Others decide that the weight of knowing outweighs anything they would do differently. Both positions are reasonable, and neither has to be settled in a single appointment.
Did you know? NCCN guidance advises that germline testing be offered to every person diagnosed with pancreatic cancer — not only to those with a striking family history, and not only to those diagnosed young. That was a deliberate move away from the older approach of selecting people by family-history criteria alone, which was found to miss a substantial share of those actually carrying an inherited variant. It is why an oncologist may raise genetic testing with you even when you are certain there is no cancer anywhere in your family: the offer is standard practice now, not a hint that something has been spotted in your history.
The situations that qualify
Where Germline Testing Is Clearly Worth Doing
These are the patterns that most often lead to testing being recommended. You do not need to match several of them — one is usually enough to justify the conversation.
A new diagnosis
Anyone diagnosed with pancreatic cancer
Offered regardless of age and regardless of family history. The result can affect which systemic options are on the table, and what your relatives are advised to do next.
A close relative
A parent, sibling or child was affected
One closely related person with pancreatic cancer is enough to make the conversation worth having, particularly if they were diagnosed young.
A family cluster
Two or more relatives on the same side
Several affected relatives on one side of a family raises the chance that something inherited runs through it, whether or not a gene is ever found.
A known variant
Someone in the family already has a result
The simplest situation of all. If a relative carries a known pathogenic variant, your test can look at that single site, and the answer is unambiguous either way.
Related cancers
Breast, ovarian, prostate, bowel or melanoma in the family
The same genes sit behind several cancers. A family history that looks unrelated to the pancreas can still point at a variant worth identifying.
A known syndrome
Lynch, Peutz-Jeghers, FAMMM or hereditary pancreatitis
Where one of these is already diagnosed or suspected in a family, testing is not exploratory — it confirms who carries it and who does not.
Two different tests
Germline Testing and Tumour Testing Are Not the Same Thing
People are often told they are “having genetic testing” without being told which one. The difference matters, because only one of them says anything about your family.
| Germline test | Tumour (somatic) test | |
|---|---|---|
| What is sampled | Your blood or saliva. | Tissue from the tumour itself, usually left over from a biopsy or a resected specimen. |
| What it looks at | The genes you inherited and carry in every cell of your body. | Changes the cancer acquired during your lifetime, present only in the tumour. |
| What it can change for you | Can open specific systemic options, and shapes long-term follow-up. | Can identify targetable features and eligibility for particular classes of treatment. |
| What it means for relatives | Directly relevant. A pathogenic result gives every blood relative something specific to test for. | Usually nothing. A tumour-only change is not inherited and cannot be passed on. |
| When it is usually done | Any time after diagnosis, often before treatment decisions are finalised. Also done in unaffected relatives. | Only when there is tumour tissue to work with, so it follows a biopsy or an operation. |
| Where it happens | Counselling, ordering and the sample at CION; the analysis at an accredited genetics laboratory. | Depends on where the tissue came from, since the biopsy itself is coordinated with partner endoscopy centres. |
If you have been handed a form and told it is “a genetic test,” it is fair to ask which of these two it is, and what will be done with the answer. Book a free consultation or call 1800 202 8726 and we will go through it with you before anything is sent off.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
A Gene Result Is Only Useful If Someone Explains It
Germline testing changes plans for you and for the people related to you. Both conversations are worth having properly.
What actually happens
What Getting Tested Actually Involves
-
A conversation before any sample is taken
What you want from the result, what it could show, and who else it would affect. This is the part people skip and later wish they had not — genetic counselling for pancreatic cancer covers that conversation in more detail.
In-house at CION -
Deciding who in the family goes first
Wherever possible, the person who had the cancer is tested first. If a variant is already known in the family, the test narrows to that single site, which is quicker and far easier to interpret.
In-house at CION -
The sample
A blood draw, or a saliva kit where a blood sample is not practical. It takes minutes, needs no fasting and no preparation, and there is nothing uncomfortable about it.
Sample taken at CION -
The laboratory analysis
A multi-gene panel is read rather than a single gene, because several inherited genes are relevant here. Results take weeks rather than days, and that wait is normal, not a sign that something has been found.
Accredited genetics laboratory -
The results appointment
Results are explained in person, not posted out as a report to decode alone. There are three possible outcomes, and the middle one — an uncertain variant — is the one most worth understanding in advance.
In-house at CION -
What follows, for you and for your family
A pathogenic result may change systemic options for you, and starts a separate conversation about testing relatives and, for carriers, structured surveillance. See pancreatic cancer treatment in Hyderabad for where the treatment side of that leads.
In-house at CION; endoscopic surveillance coordinated with partner centres
Reading the report
What Each Possible Result Actually Means
A pathogenic or likely pathogenic variant. A gene change known to raise cancer risk has been found. This is the result that changes plans — it can affect which systemic treatments are considered if you have been diagnosed, and it gives every blood relative a specific question to ask about themselves. What it does not mean is that cancer is inevitable. Carrying a variant raises risk; it does not fix an outcome, and plenty of carriers never develop the cancer their family has feared.
A variant of uncertain significance. The laboratory has found a change but cannot yet say whether it matters. This is the result that causes the most distress and prompts the fewest actions. An uncertain variant is not treated as a positive result and should not drive decisions about surgery, screening or anything else. Classifications are revisited as laboratory knowledge grows, and a good number of these findings are eventually reclassified as harmless. If you receive one, the honest position is that nothing changes today.
No variant found. Reassuring, but read it carefully. If the person tested is the one who had cancer, a negative genuinely lowers the likelihood of a recognised inherited cause running through the family. If the person tested is an unaffected relative and no affected relative was ever tested, the negative is much weaker: it may simply mean the family's variant is one the panel does not cover, or that the cause is something no current test detects. A strong family history still counts even when the panel is clear, and it can justify surveillance on its own.
None of these three results is a verdict on your health. They are pieces of information that change what is offered to you and to the people related to you, and every one of them is easier to hold once somebody has explained what it does and does not imply.
Being clear about this
What CION Does, and What Happens Elsewhere
- Genetic counselling before and after the test, in-house. Working out whether testing helps you, who in the family to test first, and what you would do with each possible answer.
- Ordering the panel and interpreting the report, in-house. The sample is taken at CION; the laboratory analysis itself is performed by an accredited genetics laboratory, and the report comes back to your oncologist to explain.
- The treatment a result can unlock, in-house across 35+ centres. PARP-inhibitor-class maintenance for BRCA-mutated disease, and immune checkpoint treatment where a tumour is mismatch-repair deficient, are given by CION medical oncology — pancreatic cancer treatment in Hyderabad sets out the wider plan those sit inside.
- Imaging and bloods, in-house. Pancreatic-protocol CT, MRI/MRCP and CA 19-9 are ordered and reported by CION, including the MRI arm of surveillance for people found to carry a variant.
- Coordinated with partner centres, and it may be billed there. Endoscopic ultrasound and biopsy, ERCP and stenting, staging laparoscopy, PET-CT and all pancreatic surgery are carried out by specialist HPB, gastroenterology and endoscopy partners. CION does not perform these in-house, and you should expect a separate bill for them.
- A free 45-minute consultation to start. Long enough to draw the family tree properly, read any report you already have, and tell you plainly whether testing would change anything for you.
- The rest of the support, in-house. Nutrition and pancreatic enzyme support, pain management, psycho-oncology for the anxiety a family history brings, and long-term follow-up.
If pancreatic cancer has appeared more than once in your family and nobody has ever explained what to do about it, that is worth an hour of someone's time. Book a free consultation, call 1800 202 8726, or start with the complete guide to pancreatic cancer if you would rather read first.
Take the next step
Testing Is a Decision, Not a Formality
You are entitled to understand what a result would change before you agree to anything. We walk this journey with you.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Genetic testing for pancreatic cancer — your questions answered
Who should have germline genetic testing for pancreatic cancer?
There are two groups. If you have been diagnosed with pancreatic cancer, NCCN guidance is that germline testing should be offered to you whatever your age and whatever your family history, because inherited variants are regularly found in people whose family tree would never have raised a question. If you have not been diagnosed, testing is usually discussed when a parent, sibling or child has had pancreatic cancer, when two or more relatives on the same side have had it, when a relative already carries a known gene result, when breast, ovarian, prostate, bowel or melanoma cancers also run in the family, or when a syndrome such as Lynch, Peutz-Jeghers, FAMMM or hereditary pancreatitis is known or suspected. A counselling appointment decides who in the family should be tested first, which matters more than most people expect.
What is the difference between germline testing and testing the tumour?
They answer different questions from different samples. Germline testing uses your blood or saliva and reads the genes you were born with and carry in every cell, so a result applies to your whole family and can be passed on. Tumour testing, sometimes called somatic or molecular profiling, uses tissue from the cancer itself and looks at changes the tumour acquired during your lifetime. Those changes are not inherited and usually mean nothing for your relatives. Both can influence treatment, so neither replaces the other. If you have been told you are having a genetic test without being told which one, it is entirely reasonable to ask, because only one of the two has anything to say about your children.
What does the test involve, and how long do results take?
The sample is simple: a routine blood draw, or a saliva kit where blood is not practical. There is no fasting, no preparation and nothing uncomfortable about it. The laboratory reads a panel of genes rather than a single gene, because several inherited genes are relevant in pancreatic cancer, though a targeted test looking for one known family variant is quicker than a full panel. Results take weeks rather than days. That wait is standard and says nothing about what has been found. The more important part of the process is not the sample at all but the two conversations around it: what you want to know beforehand, and what the report actually means afterwards.
What does a variant of uncertain significance mean?
It means the laboratory has found a change in a gene but cannot yet say whether that change causes any harm. It is not a positive result and it is not treated as one. Nobody should be offered surgery, extra surveillance or a change of treatment on the basis of an uncertain variant alone, and no relative should be tested for it as though it were a known family variant. Laboratories reclassify these findings as knowledge accumulates, and many are eventually shown to be harmless. If you receive one, the honest answer is that nothing changes today, and that your care continues to be guided by your family history and your own clinical picture rather than by the uncertain finding.
If my test comes back negative, is my family in the clear?
It depends on who was tested. If the person who actually had pancreatic cancer tested negative, that genuinely lowers the likelihood of a recognised inherited cause running through the family. If an unaffected relative was tested and nobody affected ever was, the negative is much weaker. It may simply mean the family's variant is one the panel does not cover, or that whatever is driving the pattern cannot be detected by any test available today. A strong family history still counts on its own. Where several close relatives have been affected, surveillance may still be recommended even with a clear panel, and that recommendation is not a sign that anyone doubts your result.
Does a gene result change the treatment I am offered?
It can. Where a pathogenic variant in one of the DNA-repair genes is found, a specific class of maintenance treatment becomes relevant for some people with advanced disease, and where a tumour is shown to be mismatch-repair deficient, immune checkpoint treatment enters the discussion. Neither applies to everyone with a positive result, and the decision depends on your stage, your general health and how the disease has behaved so far. That is why a gene result is discussed alongside the rest of your plan rather than in isolation. Both of these treatment classes are delivered by CION medical oncology in-house; the surgery, endoscopy and PET imaging that may sit around them are coordinated with specialist partner centres.
What does CION do about genetic testing, and what happens at the first appointment?
The first consultation is free and lasts 45 minutes. We draw out your family tree properly, read any pathology or gene report you already have, and tell you plainly whether testing would change anything for you or for anyone related to you. If testing is appropriate, counselling, ordering the panel, taking the sample and interpreting the report are all handled at CION, with the laboratory analysis performed by an accredited genetics laboratory. Imaging, bloods, chemotherapy, radiation, nutrition and enzyme support and psycho-oncology are delivered in-house across 35+ centres. Endoscopic ultrasound and biopsy, ERCP and stenting, PET-CT and all pancreatic surgery are coordinated with specialist partner centres and may be billed there. You are under no obligation to be tested.
Medical disclaimer: This page explains who germline genetic testing for pancreatic cancer is offered to and what each result means, and is reviewed by a CION medical oncologist with reference to NCCN guidance on genetic and familial high-risk assessment in pancreatic cancer. It is general information; whether testing is right for you, and who in your family should be tested first, is an individual decision to be made with your treating team and a genetic counsellor. Genetic counselling, ordering and interpretation of germline testing, chemotherapy, radiation, chemoradiation and SBRT, imaging and CA 19-9 ordering and reporting, nutrition and enzyme support, pain relief, psycho-oncology and survivorship care are delivered by CION, with laboratory analysis of the sample performed by accredited genetics laboratories; all pancreatic surgery, endoscopic ultrasound and biopsy, ERCP and stenting, staging laparoscopy, coeliac plexus block, PET-CT and DOTATATE PET, and peptide receptor radionuclide therapy are coordinated with specialist HPB, gastroenterology and endoscopy partner centres and may be billed there.